- Home
- APRE vs DUO Comparison
APRE vs DUO Comparison
Compare APRE & DUO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- DUO
- Stock Information
- Founded
- APRE 2006
- DUO 2011
- Country
- APRE United States
- DUO China
- Employees
- APRE N/A
- DUO N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- DUO Real Estate
- Sector
- APRE Health Care
- DUO Finance
- Exchange
- APRE Nasdaq
- DUO Nasdaq
- Market Cap
- APRE 10.0M
- DUO 11.4M
- IPO Year
- APRE 2019
- DUO 2019
- Fundamental
- Price
- APRE $1.80
- DUO $2.32
- Analyst Decision
- APRE Strong Buy
- DUO
- Analyst Count
- APRE 2
- DUO 0
- Target Price
- APRE $15.50
- DUO N/A
- AVG Volume (30 Days)
- APRE 50.9K
- DUO 177.1K
- Earning Date
- APRE 08-11-2025
- DUO 08-29-2025
- Dividend Yield
- APRE N/A
- DUO N/A
- EPS Growth
- APRE N/A
- DUO N/A
- EPS
- APRE N/A
- DUO 7.57
- Revenue
- APRE $1,284,475.00
- DUO $46,458,330.00
- Revenue This Year
- APRE N/A
- DUO N/A
- Revenue Next Year
- APRE N/A
- DUO N/A
- P/E Ratio
- APRE N/A
- DUO $0.31
- Revenue Growth
- APRE 33.27
- DUO 19.00
- 52 Week Low
- APRE $1.41
- DUO $1.97
- 52 Week High
- APRE $5.01
- DUO $74.72
- Technical
- Relative Strength Index (RSI)
- APRE 49.58
- DUO 37.94
- Support Level
- APRE $1.64
- DUO $1.97
- Resistance Level
- APRE $1.81
- DUO $2.49
- Average True Range (ATR)
- APRE 0.15
- DUO 0.17
- MACD
- APRE -0.01
- DUO 0.02
- Stochastic Oscillator
- APRE 51.76
- DUO 45.86
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.